Eisai builds Chinese GI portfolio with Almirall deal
This article was originally published in Scrip
Executive Summary
Eisai has acquired rights to Almirall's gastroprokinetic agent cinitapride in China, in a deal which extends the Japanese firm's gastrointestinal (GI) portfolio in this fast-growing market.